BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
39.65
+0.60 (1.54%)
Jun 12, 2025, 4:00 PM - Market closed
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$174,541
Profits / Employee
-$915,025
Market Cap
7.53B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BBIO News
- 9 days ago - BridgeBio: New Data Bolsters The Bull Case - Seeking Alpha
- 11 days ago - BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 24 days ago - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - GlobeNewsWire
- 24 days ago - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - GlobeNewsWire
- 4 weeks ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - GlobeNewsWire
- 4 weeks ago - BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - GlobeNewsWire
- 5 weeks ago - BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - GlobeNewsWire